The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Immunotherapy Largely Untested in Patients with Autoimmune Disease

Immunotherapy Largely Untested in Patients with Autoimmune Disease

June 6, 2016 • By Andrew M. Seaman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—The safety and effectiveness of cancer immunotherapy is largely unknown in patients with autoimmune diseases, researchers say—and that might account for up to a quarter of individuals with lung cancer.

You Might Also Like
  • Immunotherapy May Be Effective for Some Patients with Autoimmune Cerebellar Ataxia
  • Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer

Patients with autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis or psoriasis, have been mostly excluded from clinical trials testing immunotherapies over fears that the treatments will worsen the conditions or cause new ones to appear, because immunotherapy uses the body’s own immune system to fight cancer.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As a result, the effectiveness and potential side effects of immunotherapy are largely unknown for these patients, says senior author Dr. David Gerber of the University of Texas Southwestern Medical Center in Dallas.

To estimate how many people with lung cancer in the U.S. may have autoimmune conditions, the researchers matched government insurance data from 1991–2011 with national cancer data from 1992–2009.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, there were 210,509 patients with lung cancer, of whom 28,453, or about 14%, had been hospitalized at least once for an autoimmune disease or had at least two insurance claims for autoimmune conditions.

Using more liberal criteria—just one insurance claim for an autoimmune condition—the proportion with one of these diseases went up to nearly 25%.

Gerber says doctors can generally speculate about the possible effects immunotherapy will have among people with autoimmune diseases since it’s largely untested in that group.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“It’s because immunotherapy has demonstrated such effectiveness and promise that these questions are worth asking,” he says.

“I don’t think the concern is that effectiveness of treatment against the cancer is going to be less,” Gerber says. “I think the concern is that toxicity would be more.”

There may, however, be concern over the effectiveness of immunotherapy if the

The results were presented Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago and published online in JAMA Oncology.

Filed Under: Drug Updates Tagged With: Autoimmune disease, Cancer, immunotherapy, lung

You Might Also Like:
  • Immunotherapy May Be Effective for Some Patients with Autoimmune Cerebellar Ataxia
  • Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • IgG from Patients with Autoimmune Disease Activates Neutrophils

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.